in-lin guid ex tax/fx
rais po due lower tax rate
highlight new tax rate po
revenu non-gaap ep came forecast latter
driven primarili tax made follow chang model result
updat po vs non-gaap tax rate
share-bas comp off-set roughli half repo tone
recoveri speed steril inject franchis base management commentari trim
outer-year sg initi sale ep guidanc mid-point
compar updat forecast respect
valu use blend valuat dcf wacc termin growth
rate price-to-earnings reiter buy rate due key growth brand
differenti enjoy first-mov advantag diversifi us major
takeaway call
focu result updat effect tax rate
expect sustain forese futur capit deploy prioriti
unchang mid-singl digit dividend growth repo in-lin
although compani note review capit alloc opportun lieu
tax reform ibranc eu one-tim price adjust pay true-up
revenu book higher provision price higher go-forward
negoti price indic adjust compar eu oncolog
analog management emphas adjust part final broader reimburs
negoti chang ibranc eu demand dont forese spillov
adjust market commentari remain high prioriti
deter valuat paid deal note everi deal specif xtandi
prostat cancer expect number patient enrol non-revenu gener
patient-assist program ytd lower consum strateg
review remain open-end complet process option
remain consider
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
global biopharmaceut compani
diversifi portfolio product pipelin
candid one largest pharma
compani world measur market
capit revenu compon
jone industri averag compani
commerci oper bifurc two
busi segment innov ih
essenti eh gener
revenu total
view compani current valuat
undemand rel compani forward
ep growth face modest near-
term patent cliff encourag recent
event strengthen market leadership
key innov space offer attract
view sustain dividend
on-going strateg review consum busi
state intent engag post us tax
reform outcom could enhanc sharehold
exhibit pfizer ep guidanc
market sale administr non-gaap
billion
billion
approxim million incom
price object po base blend averag dcf forward price-to-earnings po
impli stock trade ep current
multipl consensu ep multipl base
regress analysi histor us major pharma forward month price-to-earnings multipl
year forward compound-annual-growth-rate ep believ dcf analysi base reason
assumpt includ modest sale growth compound-annual-growth-rate
respect reflect loss exclus lyrica viagra collect
account us sale forecast near-term headwind
off-set key growth brand xeljanz ibranc xtandi flat
sale growth follow downward rebas us sale pipelin
overal sale forecast out-year sale dcf
assum wacc tgr
risk sale downsid us sale continu declin and/or competit
take meaning market share ibranc could lead downsid estim
po inabl grow busi in-lin forecast hold opex
spend flat level throughout forecast period transact
perceiv valu destruct dcf analysi reflect valu futur
 transact core element strategi
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us major specialti pharmaceut coverag cluster
compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
